X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fiercebiotech.com/biotech/ascletis-pulls-fxr-agonist-pipeline-over-phase-2-primary-biliary-cholangitis-data
https://www.globenewswire.com/news-release/2024/03/27/2853583/0/en/Sagimet-Biosciences-Announces-Completion-of-Phase-1-Hepatic-Impairment-Study-with-FASN-Inhibitor-Denifanstat.html
https://www.globenewswire.com/news-release/2024/03/25/2851458/0/en/Sagimet-Biosciences-Reports-Full-Year-2023-Financial-Results-and-Provides-Corporate-Updates.html
https://www.prnewswire.com/news-releases/gannexs-strategic-partner-sagimet-biosciences-announces-positive-topline-results-from-phase-2b-fascinate-2-clinical-trial-of-denifanstat-in-biopsy-confirmed-f2f3-nash-302041397.html
https://www.prnewswire.com/news-releases/ascletis-announces-initiation-of-phase-iii-clinical-trial-of-asc40-denifanstat-for-treatment-of-acne-302005533.html
https://www.globenewswire.com/news-release/2023/06/23/2693413/0/en/Sagimet-Biosciences-Presents-Positive-Phase-2b-FASCINATE-2-Clinical-Trial-Interim-Data-for-Denifanstat-for-the-Treatment-of-NASH-at-EASL-Congress-2023.html
https://www.globenewswire.com/news-release/2023/06/07/2683801/0/en/Sagimet-Biosciences-to-Present-Interim-Data-from-Phase-2b-Trial-of-Denifanstat-in-NASH-at-EASL-Congress-2023.html
https://www.prnewswire.com/news-releases/ascletis-announces-completion-of-180-patient-enrollment-for-phase-ii-clinical-trial-of-fasn-inhibitor-asc40-for-acne-301690157.html
Market Place
Share 
